Loading…
Improving Access to Transfusion Care for Hospice Patients Act of 2025
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,674 other S bills in the 119th — cohort avg 32d
Improving Access to Transfusion Care for Hospice Patients Act of 2025 This bill requires the Center for Medicare and Medicaid Innovation (CMMI) to test a model under which blood transfusions furnished to an individual receiving hospice care are paid separately from the hospice all-inclusive per diem payment under Medicare. The CMMI must evaluate the model by comparing patients participating in the model with those outside of the model in relation to specified metrics, such as hospital utilization and days of hospice care before the end of life.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2026 · third_quarter · Health Issues
Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Issues related to H-1B visas for physician workforce Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Sickle Cell Care Expansion Act of 2026 (S. 5489) Sickle Cell Disease Treatment Centers Act of 2026 (S. 5488) Resolutions expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" (H.Res. 1577 / S.Res. 940)
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $100,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), SENATE
2026 · third_quarter · Medicare/Medicaid
Coverage of blood transfusions under Medicare hospice benefit Medicare physician reimbursement issues CMS national coverage determinations for autologous stem cell transplantation for multiple myeloma Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Issues related to CAR-T/cellular and gene therapies Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Issues related to Social Security Administration disability evaluations for sickle cell disease Impact of Medicaid funding cuts on hematology Medicare codes for Chronic Care Management (CCM) and Principal Care Management (PCM) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Community engagement requirements of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936 / H.R. 9703) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)
Client expense: $100,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Social Security Administration (SSA)
2026 · third_quarter · Medicare/Medicaid
HR 3514 / S 1816, the Improving Seniors Timely Access to Care Act; HR 5243, a bill to increase data transparency for supplemental benefits under Medicare Advantage; HR 8375 / S 4384, the Medicare Advantage Improvement Act; HR 9392, Medicare Advantage Cost Transparency Act; S 1105, No UPCODE Act; S 1629, Same Care, Lower Cost Act; S 1936, Improving Access to Transfusion Care for Patients Act; S 4886, Medicare Cost Cap Act; CMS Interim Final Rule on Medicaid Work Requirements; Regulatory and legislative proposals to expand site-neutral payment in Medicare; Implementation of the Accelerating Kids Access to Care Act (HR 1509, S 752) Regulatory proposals related to most-favored nation drug pricing; Issues related to the cost of care, including consolidation and anti-competitive contracting
Client expense: $120,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medicare/Medicaid
HR 3514, Improving Seniors Timely Access to Care Act; HR 5243, a bill to increase data transparency for supplemental benefits under Medicare Advantage; HR 9392, Medicare Advantage Cost Transparency Act; S 1105, No UPCODE Act; S 1629, Same Care, Lower Cost Act; S 1936, Improving Access to Transfusion Care for Patients Act; S 4886, Medicare Cost Cap Act; CMS Interim Final Rule on Medicaid work requirements; Regulatory and legislative proposals to expand site-neutral payment in Medicare; Implementation of the Accelerating Kids Access to Care Act (HR 1509, S 752); Regulatory proposals related to most-favored-nation drug pricing;
Client expense: $590,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Issues related to H-1B visas for physician workforce Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)
Client expense: $100,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), SENATE
2026 · second_quarter · Medicare/Medicaid
Coverage of blood transfusions under Medicare hospice benefit Medicare physician reimbursement issues CMS national coverage determinations Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Issues related to CAR-T/cellular and gene therapies Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Issues related to Social Security Administration disability evaluations for sickle cell disease Impact of Medicaid funding cuts on hematology Medicare codes for Chronic Care Management (CCM) and Principal Care Management (PCM) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)
Client expense: $100,000 · Firm income: Not reported
2026 · first_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Extension of Affordable Care Act enhanced advance premium tax credits Issues related to H-1B visas for physician workforce
Client expense: $100,000 · Firm income: Not reported
2026 · first_quarter · Medicare/Medicaid
Coverage of blood transfusions under Medicare hospice benefit Medicare physician reimbursement issues Issues related to CAR-T/cellular and gene therapies Implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10) Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) CMS national coverage determinations Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries National Coverage Decision for hematopoietic stem cell transplantation (HSCT) for MDS Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Issues related to Social Security Administration disability evaluations for sickle cell disease Impact of Medicaid funding cuts on hematology Medicare codes for Chronic Care Management (CCM) and Principal Care Management (PCM) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)
Client expense: $100,000 · Firm income: Not reported
2025 · fourth_quarter · Medicare/Medicaid
Coverage of blood transfusions under Medicare Hospice Benefit Medicare physician reimbursement issues Issues related to CAR-T/cellular and gene therapies Implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10) Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) CMS national coverage determinations Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries National Coverage Decision for hematopoietic stem cell transplantation (HSCT) for MDS Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Impact of proposed Medicaid funding cuts on hematology Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)
Client expense: $30,000 · Firm income: Not reported
2025 · fourth_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Extension of Affordable Care Act enhanced advance premium tax credits Issues related to H-1B visas for physician workforce
Client expense: $30,000 · Firm income: Not reported
2025 · third_quarter · Medicare/Medicaid
Coverage of blood transfusions under Medicare Hospice Benefit Medicare physician reimbursement issues Issues related to CAR-T/cellular and gene therapies Implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10) Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) CMS national coverage determinations Medicaid coverage for sickle cell disease Issues related to telemedicine/telehealth Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries National Coverage Decision for hematopoietic stem cell transplantation (HSCT) for MDS Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Impact of proposed Medicaid funding cuts on hematology One Big Beautiful Bill Act (H.R. 1) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936)
Client expense: $30,000 · Firm income: Not reported
2025 · third_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) One Big Beautiful Bill Act (H.R. 1) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Extension of Affordable Care Act enhanced advance premium tax credits Issues related to H-1B visas for physician workforce
Client expense: $30,000 · Firm income: Not reported
2025 · second_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and abortion access Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Sickle Cell Disease Comprehensive Care Act (S. 721) One Big Beautiful Bill Act (H.R. 1) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936)
Client expense: $30,000 · Firm income: Not reported
2025 · second_quarter · Medicare/Medicaid
Coverage of blood transfusions under Medicare Hospice Benefit Medicare physician reimbursement issues Issues related to CAR-T/cellular and gene therapies Implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10) Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) CMS national coverage determinations Medicaid coverage for sickle cell disease Issues related to telemedicine/telehealth Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries National Coverage Decision for hematopoietic stem cell transplantation (HSCT) for MDS Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Impact of proposed Medicaid funding cuts on hematology One Big Beautiful Bill Act (H.R. 1) Sickle Cell Disease Comprehensive Care Act (S. 721) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936)
Client expense: $30,000 · Firm income: Not reported
2025 · second_quarter · Health Issues
Issues related to hospice, specifically: - Hospice benefit and payment H.R. 2437 - End-of-life Access to Supportive and Essential care Act of 2025 S. 1935 - Expanding Access to Palliative Care Act S. 1936 - Improving Access to Transfusion Care for Hospice Patients Act of 2025 - Hospice audit burdens and regulatory relief Policies related to implementation of the Hospice Outcomes and Patient Evaluation (HOPE) assessment tool - Pediatric Hospice and Palliative Care - Medicare Advantage H.R. 3467 - To amend title XVIII to reform the Medicare Advantage program (as it relates to hospice carve-in) - Program Integrity - Hospice Special Focus Program - Telehealth flexibilities: S. 1261 - CONNECT for Health Act of 2025 H.R. 1720 - Hospice Recertification Flexibility Act H.R. 1968 (P.L. 119-4) - Full-Year Continuing Appropriations and Extension Act, 2025 - Hospice and palliative care workforce - Veterans access and use of hospice and VA burial benefits Implementation of the Dole Act Issues related to home health, specifically: - Extending Telehealth Flexibilities - Home Health benefit and payment - Patient-Driven Groupings Model Isses related to home care, specifically: - Caregiving relief H.R. 2036/S. 925 - Credit for Caring Act of 2025 H.R. 2304 - Ensuring Access to Affordable and Quality Home Care for Seniors Act (restoration of the Companion Exemption)
Client expense: $530,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Social Security Administration (SSA)
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Social Security Administration (SSA)
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE